{"id":556855,"date":"2026-02-25T00:00:00","date_gmt":"2026-02-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0004-2025-biopharma-crohns-disease-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-04-25T11:14:20","modified_gmt":"2026-04-25T11:14:20","slug":"dlsfim0004-2026-biopharma-crohns-disease-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0004-2026-biopharma-crohns-disease-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Crohn&#8217;s Disease &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>The Crohn\u2019s disease (<abbr data-abbreviation-entity=\"4751\" title=\"Crohn's disease\">CD<\/abbr>) therapy market will grow steadily over the next 10 years as a result of the increasing use of biologics \/ targeted oral therapies. The well-established <abbr data-abbreviation-entity=\"4976\" title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors (e.g., infliximab [J&#038;J Innovative Medicine\u2019s Remicade, biosimilars], adalimumab [AbbVie \/ Eisai\u2019s Humira, biosimilars]) and the non-<abbr data-abbreviation-entity=\"4976\" title=\"tumor necrosis factor\">TNF<\/abbr> biologics (i.e., Takeda\u2019s Entyvio and J&#038;J Innovative Medicine\u2019s Stelara) have transformed the treatment of CD, especially for moderate to severe disease, despite these drugs\u2019 limitations in efficacy and safety. The recent approvals and emergence of several new therapies offering more-convenient formulations and\/or novel mechanisms of action (e.g., AbbVie\u2019s Skyrizi and Rinvoq, Eli Lilly\u2019s Omvoh, J&#038;J Innovative Medicine\u2019s Tremfya) will further enhance treatment and increase market competition. Sales growth will be constrained by factors including the continuing generic erosion of conventional agents and the availability of biosimilars of <abbr data-abbreviation-entity=\"4976\" title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors and <abbr data-abbreviation-entity=\"4864\" title=\"interleukin\">IL<\/abbr>-12\/23 inhibitors.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are <abbr data-abbreviation-entity=\"5534\" title=\"key opinion leader\">KOL<\/abbr>s\u2019 opinions of current targeted therapies (e.g., infliximab, adalimumab, Stelara, Entyvio) for <abbr data-abbreviation-entity=\"4751\" title=\"Crohn's disease\">CD<\/abbr>? How have biosimilars influenced treatment practices? What factors drive treatment decisions?<\/li>\n<li>What are <abbr data-abbreviation-entity=\"5534\" title=\"key opinion leader\">KOL<\/abbr>s\u2019 views on recently approved and emerging therapies (e.g., Skyrizi, Rinvoq, Omvoh, Tremfya) for <abbr data-abbreviation-entity=\"4751\" title=\"Crohn's disease\">CD<\/abbr>? What impact will the oral therapies have on the <abbr data-abbreviation-entity=\"4751\" title=\"Crohn's disease\">CD<\/abbr> treatment algorithm?<\/li>\n<li>Which emerging agents are likely to be the most successful targeting <abbr data-abbreviation-entity=\"4976\" title=\"tumor necrosis factor\">TNF<\/abbr>-refractory patients and experiencing uptake in the <abbr data-abbreviation-entity=\"4751\" title=\"Crohn's disease\">CD<\/abbr> market?<\/li>\n<li>How will the market evolve over the next 10 years?<\/li>\n<\/ul>\n<p><strong>CONTENT <\/strong><strong>HIGHLIGHTS<\/strong><\/p>\n<p><strong>Geographies:<\/strong> United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan.<\/p>\n<p><strong>Primary research: <\/strong>26 country-specific interviews with thought-leading gastroenterologists supported by survey data collected for this and other Clarivate research.<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed prevalence of <abbr title=\"Crohn's disease\">CD<\/abbr> by country, segmented by disease activity.<\/p>\n<p><strong>Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key <abbr title=\"Crohn's disease\">CD<\/abbr> therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations.<\/p>\n<p><strong>Drug treatments:<\/strong> Coverage of key current and late-phase emerging therapies.<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul>\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-556855","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-therapy-areas-gastrointestinal","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/556855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/556855\/revisions"}],"predecessor-version":[{"id":575189,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/556855\/revisions\/575189"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=556855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}